Literature DB >> 12218291

Isolation and characterization of thomsen-friedenreich-specific antibodies from human serum.

Günter Butschak1, Uwe Karsten.   

Abstract

The Thomsen-Friedenreich (TF) disaccharide, galactose (Gal)beta1-3GalNAcalpha-, is a blood group-related oncofetal antigen with remarkable tumor specificity. Postpartum, carbohydrate structures on the cell walls of the gastrointestinal flora evoke natural antibodies of presumed TF specificity. These antibodies may provide an early barrier against TF-carrying tumor cells. Their possible role, however, has been difficult to assess, since so far only a multivalent immunosorbent, asialoglycophorin (aGP), has been employed for their preparation, and therefore their fine specificities have been only insufficiently defined. We have used a novel immunosorbent consisting of synthetic TFalpha disaccharides (Galbeta1-3GalNAcalpha-) coupled to polyacrylamide (PAA), which itself was covalently bound to cross-linked sepharose. For specificity analyses, aGP and a panel of PAA-conjugated mono- and oligosaccharides were employed. Binding to the PAA moiety was excluded. The affinity-purified anti-TFalpha antibodies were of the IgM (> or =0.5 mg/100 ml of serum) and IgG (approximately 0.05 mg/100 ml of serum) classes. They did partially cross-react with TFbeta, although we detected a second group of anti-TFbeta antibodies (both IgM and IgG) which did not cross-react with TFalpha. The affinity-purified TFalpha antibodies showed only marginal cross-reactivity with the related antigens lactose, Gal, Tn or the Forssman antigen. Besides TF-specific antibodies, we found antibodies to the carbohydrate antigens Tn, Forssman and beta-D-Gal as well as to noncarbohydrate epitopes of glycophorin in human serum. Copyright 2002 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12218291     DOI: 10.1159/000064026

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  8 in total

1.  Binding of galectin-1 (gal-1) to the Thomsen-Friedenreich (TF) antigen on trophoblast cells and inhibition of proliferation of trophoblast tumor cells in vitro by gal-1 or an anti-TF antibody.

Authors:  Udo Jeschke; Uwe Karsten; Irmi Wiest; Sandra Schulze; Christina Kuhn; Klaus Friese; Hermann Walzel
Journal:  Histochem Cell Biol       Date:  2006-04-11       Impact factor: 4.304

2.  The Potential Action of Thomsen-Friedenreich Monoclonal Antibody (A78-G/A7) in Thyroid Cancer.

Authors:  Ying Peng; Xiang-Xiang Zhan; Yi Cao; Han-Wen Zhang; Wei-Han Cao; Yan-Jun Su; Chang Diao; Qiang-Ming Sun; Ruo-Chuan Cheng
Journal:  Onco Targets Ther       Date:  2020-08-25       Impact factor: 4.147

3.  Specificity of human anti-carbohydrate IgG antibodies as probed with polyacrylamide-based glycoconjugates.

Authors:  E P Smorodin; O A Kurtenkov; B L Sergeyev; G V Pazynina; N V Bovin
Journal:  Glycoconj J       Date:  2004       Impact factor: 2.916

4.  Tumor-associated glycans and their role in gynecological cancers: accelerating translational research by novel high-throughput approaches.

Authors:  Tatiana Pochechueva; Francis Jacob; Andre Fedier; Viola Heinzelmann-Schwarz
Journal:  Metabolites       Date:  2012-11-14

5.  The relation of the level of serum anti-TF, -Tn and -alpha-Gal IgG to survival in gastrointestinal cancer patients.

Authors:  Eugeniy Smorodin; Boris Sergeyev; Kersti Klaamas; Valentin Chuzmarov; Oleg Kurtenkov
Journal:  Int J Med Sci       Date:  2013-09-23       Impact factor: 3.738

Review 6.  Tumor-Associated Glycans and Immune Surveillance.

Authors:  Behjatolah Monzavi-Karbassi; Anastas Pashov; Thomas Kieber-Emmons
Journal:  Vaccines (Basel)       Date:  2013-06-17

Review 7.  Breast Cancer Immunotherapy: An Update.

Authors:  Issam Makhoul; Mohammad Atiq; Ahmed Alwbari; Thomas Kieber-Emmons
Journal:  Breast Cancer (Auckl)       Date:  2018-05-30

Review 8.  Profiling of Naturally Occurring Antibodies to the Thomsen-Friedenreich Antigen in Health and Cancer: The Diversity and Clinical Potential.

Authors:  Oleg Kurtenkov
Journal:  Biomed Res Int       Date:  2020-03-23       Impact factor: 3.411

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.